Haleon Cuts 2026 Growth Guidance After Q3 Miss, Shares Hit 52-Week Low
HLN is trading near its 52-week low of $8.41 (0.2% above the low).
Summary
Haleon cut its 2026 organic revenue growth outlook to roughly 2.5% from a prior 3%-5% range after Q3 organic growth came in at 2.6%, below its own expectations. Q3 sales were £2.868 billion, with pricing contributing 2.1 points and volume/mix just 0.5 points — a thin volume base. CEO Brian McNamara pointed to weaker cough, cold and flu consumption, which also held back North American retail restocking even as Oral Health grew 8.8% to £930 million and North America rose 2.5% to £992 million. Two discrete drags sit on top of the soft demand: China halted Centrum OTC imports after an unexpected raw material reclassification (about £75 million of 2025 revenue affected, food-registered lines untouched), and an accelerated Brazil go-to-market rollout will cut Q4 net revenue by £15-20 million. Management reiterated high-single-digit adjusted operating profit growth at constant currency and started a new £500 million buyback running through no later than 19 February 2027, but the growth reset is the story — shares fell 14.5% to $8.53 and set a new 52-week low. Full-year results in February are the next checkpoint on whether the 2.5% floor holds.
At the time of this announcement, HLN was trading at $8.43 on NYSE in the Life Sciences sector, with a market capitalization of approximately $43.8B. The 52-week trading range was $8.41 to $11.28. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Benzinga.